CogUK

• Research type

  Research Study

• Full title

  A randomised, prospective study, assessing changes in cerebral function in treatment naive HIV-1 infected subjects commencing either boosted atazanavir with Truvada or boosted darunavir with maraviroc/lamivudine.

• IRAS ID

  81640

• Contact name

  Alan Winston

• Sponsor organisation

  Imperial College

• Eudract number

  2011-002656-14

• Clinicaltrials.gov Identifier

  NCT01367236

• Research summary

  When commencing antiretroviral therapy (anti-HIV therapy) for the first time, improvements in brain function are frequently observed. For example memory and concentration may improve. However, whether these improvements may differ between different anti-HIV therapies is largely unknown. The purpose of this study is to compare two different combination anti-HIV therapies over 48 weeks and to assess if differences in improvement in the function of the brain are observed over this period.The study will compare two anti-HIV therapy combinations which are currently in use and assessments will be by questionnaires, computerised testing programmes and brain scans at the beginning and end of the study. Lumbar puncture examination will also take place at the end of the study.

• REC name

  London - City & East Research Ethics Committee

• REC reference

  11/LO/1034

• Date of REC Opinion

  26 Sep 2011

• REC opinion

  Further Information Favourable Opinion